Foghorn Therapeutics Inc. (FHTX): R&D Expense
$85.47M
Year ended 2025-12-31
$78.83M
Trailing 12 months to 2026-06-30
-6.8%
3-year compound annual growth
+8.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.47M | -9.6% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $94.53M | -13.8% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $109.69M | +3.9% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $105.62M | +31.5% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $80.33M | +39.2% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $57.72M | +30.1% | 2022-08-09, From 2020-01-01 |
| 2019-12-31 | $44.36M | n/a | 2021-03-18, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
Compare FHTX, VSTM, ZOMDF, CUE side by side · Screen every company in Pharmaceutical Preparations ↗